NCT03579654View on ClinicalTrials.gov

Study of Proscavax Vaccine in Patients With Localized Prostate Cancer vs Active Surveillance

PHASE2UnknownINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

February 28, 2019

Primary Completion Date

February 28, 2021

Study Completion Date

June 30, 2022

Conditions
Prostate Cancer
Interventions
BIOLOGICAL

Proscavax

Proscavax is a prostate cancer vaccine which combines the prostate antigen PSA with immune stimulatory cytokines (IL-2 and GM-CSF).

Trial Locations (2)

02215-5400

Beth Israel Deaconess Medical Center, Boston

02215

Dana Farber Cancer Institute, Boston

Sponsors
All Listed Sponsors
lead

OncBioMune Pharmaceuticals

OTHER